Search

Your search keyword '"Poeschel, Viola"' showing total 238 results
Start Over Author "Poeschel, Viola"
238 results on '"Poeschel, Viola"'

1. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma

Author

Christofyllakis, Konstantinos, Kaddu-Mulindwa, Dominic, Lesan, Vadim, Rixecker, Torben, Kos, Igor Age, Held, Gerhard, Regitz, Evi, Pfreundschuh, Michael, Bittenbring, Joerg Thomas, Thurner, Lorenz, Poeschel, Viola, Ziepert, Marita, Altmann, Bettina, and Bewarder, Moritz

Published
2024
Full Text
View/download PDF

2. Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration

Author

Frontzek, Fabian, Renaud, Loïc, Dührsen, Ulrich, Poeschel, Viola, Bernard, Sophie, Chartier, Loïc, Ketterer, Nicolas, Récher, Christian, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Mounier, Nicolas, Tilly, Hervé, Morschhauser, Franck, Le Gouill, Steven, Karsten, Imke E., Duns, Gerben, Steidl, Christian, Scott, David W., Klapper, Wolfram, Rosenwald, Andreas, Ott, German, Molina, Thierry, Lenz, Georg, Ziepert, Marita, Altmann, Bettina, Thieblemont, Catherine, and Schmitz, Norbert

Published
2024
Full Text
View/download PDF

4. Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)

Author

Tournilhac, Olivier, Altmann, Bettina, Friedrichs, Birte, Bouabdallah, Kamal, Leclerc, Mathieu, Cartron, Guillaume, Turlure, Pascal, Reimer, Peter, Wagner-Drouet, Eva, Sanhes, Laurence, Houot, Roch, Roussel, Murielle, Kroschinsky, Frank, Dreger, Peter, Viardot, Andreas, de Leval, Laurence, Rosenwald, Andreas, Gaulard, Philippe, Wulf, Gerald, Villate, Alban, Latiere, Christelle, Elmaagacli, Ahmet, Glass, Bertram, Poeschel, Viola, Damaj, Gandhi, Sibon, David, Durot, Eric, Bilger, Karin, Banos, Anne, Haenel, Mathias, Dreyling, Martin, Keller, Ulrich, Tiab, Mourad, Drenou, Bernard, Cornillon, Jérome, Nguyen, Stéphanie, Robin, Marie, Nickelsen, Maike, Trümper, Lorenz, Lenz, Georg, Ziepert, Marita, and Schmitz, Norbert

Published
2024
Full Text
View/download PDF

5. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Author

Thieblemont, Catherine, Altmann, Bettina, Frontzek, Fabian, Renaud, Loïc, Chartier, Loic, Ketterer, Nicolas, Récher, Christian, Poeschel, Viola, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Morschhauser, Franck, Glass, Bertram, Mounier, Nicolas, Tilly, Herve, Rosenwald, Andreas, Ott, German, Lenz, Georg, Molina, Thierry, Ziepert, Marita, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

6. Comparison of R‐CHOP‐14 and R‐mini‐CHOP in older adults with diffuse large B‐cell lymphoma—A retrospective multicenter cohort study.

Author

Dilbaz, Zelal Guel, Denker, Sophy, Ankermann, Carla, Bittenbring, Joerg‐Thomas, Kaddu‐Mulindwa, Dominic, Kunte, Ameya S., Hünecke, Sascha, Poeschel, Viola, Stilgenbauer, Stephan, Thurner, Lorenz, Na, Il‐Kang, Bewarder, Moritz, and Christofyllakis, Konstantinos

Subjects
OLDER people, OVERALL survival, COHORT analysis, LYMPHOMAS, RETROSPECTIVE studies
Abstract

Diffuse large B‐cell lymphoma (DLBCL) is the most common lymphoma entity, and its incidence increases with age. There is a paucity of data regarding use of biweekly R‐CHOP (R‐CHOP‐14) in patients ≥80 years of age. We performed a retrospective cohort study of patients with DLBCL aged ≥80 years treated with R‐CHOP‐14 and R‐miniCHOP in two academic tertiary centers in Germany between 01/01/2005 and 12/30/2019. Overall, 79 patients were included. Median age was 84 years (range 80–91). Despite higher CR rates with R‐CHOP‐14 (71.4% vs. 52.4%), no statistically significant difference could be found between patients treated with R‐CHOP‐14 and R‐miniCHOP regarding overall survival (OS) (p =.88, HR 0.94, 95% CI = 0.47–1.90) and progression‐free survival (PFS) (p =.26, HR 0.66, 95% CI = 0.32–1.36). At a median follow‐up of 40 months, the 2‐year OS rates were 56% with R‐CHOP‐14 and 53% with R‐miniCHOP. Two‐year PFS rates were 46% for R‐CHOP‐14 and 50% for R‐mini‐CHOP. Relative dose intensity of chemotherapy did not correlate with OS (p =.72). With the caveat of a retrospective cohort study, we conclude that lacking a difference in OS, R‐miniCHOP should be preferred for most patients with untreated DLBCL aged ≥80 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

Author

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Marita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas, Thurner, Lorenz, Pfreundschuh, Michael, Christofyllakis, Konstantinos, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus, Hallek, Michael, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz, and Rixecker, Torben Millard

Published
2022
Full Text
View/download PDF

8. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Author

Thurner, Lorenz, Fadle, Natalie, Bittenbring, Jörg Thomas, Regitz, Evi, Schuck, Rita, Cetin, Onur, Stuhr, Ariane, Rixecker, Torben, Murawski, Niels, Poeschel, Viola, Kaddu-Mulindwa, Dominic, Preuss, Klaus-Dieter, Stilgenbauer, Stephan, Hermine, Olivier, Kluin-Nelemans, Hanneke C., Hartmann, Sylvia, Dreyling, Martin, Pott, Christiane, Bewarder, Moritz, and Hoster, Eva

Published
2021
Full Text
View/download PDF

9. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Author

Schmitz, Norbert, Truemper, Lorenz, Bouabdallah, Krimo, Ziepert, Marita, Leclerc, Mathieu, Cartron, Guillaume, Jaccard, Arnaud, Reimer, Peter, Wagner, Eva, Wilhelm, Martin, Sanhes, Laurence, Lamy, Thierry, de Leval, Laurence, Rosenwald, Andreas, Roussel, Muriel, Kroschinsky, Frank, Lindemann, Walter, Dreger, Peter, Viardot, Andreas, Milpied, Noël, Gisselbrecht, Christian, Wulf, Gerald, Gyan, Emmanuel, Gaulard, Philippe, Bay, Jacques Olivier, Glass, Bertram, Poeschel, Viola, Damaj, Gandhi, Sibon, David, Delmer, Alain, Bilger, Karin, Banos, Anne, Haenel, Mathias, Dreyling, Martin, Metzner, Bernd, Keller, Ulrich, Braulke, Friederike, Friedrichs, Birte, Nickelsen, Maike, Altmann, Bettina, and Tournilhac, Olivier

Published
2021
Full Text
View/download PDF

10. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

Author

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Held, Gerhard, Angel, Stephanie, Stilgenbauer, Stephan, Thurner, Lorenz, Bewarder, Moritz, Schwier, Maren, Pfreundschuh, Michael, Löffler, Markus, Menhart, Karin, Grosse, Jirka, Ziepert, Marita, Herrmann, Ken, Dührsen, Ulrich, Hüttmann, Andreas, Barbato, Francesco, Poeschel, Viola, and Hellwig, Dirk

Published
2021
Full Text
View/download PDF

12. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma : Pathogenesis and Patient Outcomes

Author

Noerenberg, Daniel, Briest, Franziska, Hennch, Cornelius, Yoshida, Kenichi, Hablesreiter, Raphael, Takeuchi, Yasuhide, Ueno, Hiroo, Staiger, Annette M., Ziepert, Marita, Asmar, Fazila, Locher, Benjamin N., Toth, Erika, Weber, Thomas, Amini, Rose-Marie, Klapper, Wolfram, Bouzani, Maria, Poeschel, Viola, Rosenwald, Andreas, Held, Gerhard, Campo, Elias, Ishaque, Naveed, Stamatopoulos, Kostas, Kanellis, George, Anagnostopoulos, Ioannis, Bullinger, Lars, Goldschmidt, Neta, Zinzani, Pier Luigi, Bödör, Csaba, Rosenquist, Richard, Vassilakopoulos, Theodoros P., Ott, German, Ogawa, Seishi, Damm, Frederik, Noerenberg, Daniel, Briest, Franziska, Hennch, Cornelius, Yoshida, Kenichi, Hablesreiter, Raphael, Takeuchi, Yasuhide, Ueno, Hiroo, Staiger, Annette M., Ziepert, Marita, Asmar, Fazila, Locher, Benjamin N., Toth, Erika, Weber, Thomas, Amini, Rose-Marie, Klapper, Wolfram, Bouzani, Maria, Poeschel, Viola, Rosenwald, Andreas, Held, Gerhard, Campo, Elias, Ishaque, Naveed, Stamatopoulos, Kostas, Kanellis, George, Anagnostopoulos, Ioannis, Bullinger, Lars, Goldschmidt, Neta, Zinzani, Pier Luigi, Bödör, Csaba, Rosenquist, Richard, Vassilakopoulos, Theodoros P., Ott, German, Ogawa, Seishi, and Damm, Frederik

Abstract

Purpose Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive lymphoma predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking. Patients and Methods To elucidate the full spectrum of genomic alterations, samples from 340 patients with previously untreated PMBCL were investigated by whole-genome (n = 20), whole-exome (n = 78), and targeted (n = 308) sequencing. Statistically significant prognostic variables were identified using a multivariable Cox regression model and confirmed by L1/L2 regularized regressions. Results Whole-genome sequencing revealed a commonly disrupted p53 pathway with nonredundant somatic structural variations (SVs) in TP53-related genes (TP63, TP73, and WWOX) and identified novel SVs facilitating immune evasion (DOCK8 and CD83). Integration of mutation and copy-number data expanded the repertoire of known PMBCL alterations (eg, ARID1A, P2RY8, and PLXNC1) with a previously unrecognized role for epigenetic/chromatin modifiers. Multivariable analysis identified six genetic lesions with significant prognostic impact. CD58 mutations (31%) showed the strongest association with worse PFS (hazard ratio [HR], 2.52 [95% CI, 1.50 to 4.21]; P < .001) and overall survival (HR, 2.33 [95% CI, 1.14 to 4.76]; P = .02). IPI high-risk patients with mutated CD58 demonstrated a particularly poor prognosis, with 5-year PFS and OS rates of 41% and 58%, respectively. The adverse prognostic significance of the CD58 mutation status was predominantly observed in patients treated with nonintensified regimens, indicating that dose intensification may, to some extent, mitigate the impact of this high-risk marker. By contrast, DUSP2-mutated patients (24%) displayed durable responses (PFS: HR, 0.2 [95% CI, 0.07 to 0.55]; P = .002) and prolonged OS (HR, 0.11 [95% CI, 0.01 to 0.78]; P = .028). Upon CHOP-like treatment, these patients had very favorable outcome, with 5-year PFS

Published
2024
Full Text
View/download PDF

13. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Author

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, de Nully Brown, Peter, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, and Pfreundschuh, Michael

Published
2019
Full Text
View/download PDF

14. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes

Author

Noerenberg, Daniel, primary, Briest, Franziska, additional, Hennch, Cornelius, additional, Yoshida, Kenichi, additional, Hablesreiter, Raphael, additional, Takeuchi, Yasuhide, additional, Ueno, Hiroo, additional, Staiger, Annette M., additional, Ziepert, Marita, additional, Asmar, Fazila, additional, Locher, Benjamin N., additional, Toth, Erika, additional, Weber, Thomas, additional, Amini, Rose-Marie, additional, Klapper, Wolfram, additional, Bouzani, Maria, additional, Poeschel, Viola, additional, Rosenwald, Andreas, additional, Held, Gerhard, additional, Campo, Elías, additional, Ishaque, Naveed, additional, Stamatopoulos, Kostas, additional, Kanellis, George, additional, Anagnostopoulos, Ioannis, additional, Bullinger, Lars, additional, Goldschmidt, Neta, additional, Zinzani, Pier Luigi, additional, Bödör, Csaba, additional, Rosenquist, Richard, additional, Vassilakopoulos, Theodoros P., additional, Ott, German, additional, Ogawa, Seishi, additional, and Damm, Frederik, additional

Published
2023
Full Text
View/download PDF

15. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Author

Thurner, Lorenz, Preuss, Klaus-Dieter, Bewarder, Moritz, Kemele, Maria, Fadle, Natalie, Regitz, Evi, Altmeyer, Sarah, Schormann, Claudia, Poeschel, Viola, Ziepert, Marita, Walter, Silke, Roth, Patrick, Weller, Michael, Szczepanowski, Monika, Klapper, Wolfram, Monoranu, Camelia, Rosenwald, Andreas, Möller, Peter, Hartmann, Sylvia, Hansmann, Martin-Leo, Mackensen, Andreas, Schäfer, Henning, Schorb, Elisabeth, Illerhaus, Gerald, Buslei, Rolf, Bohle, Rainer Maria, Stilgenbauer, Stephan, Kim, Yoo-Jin, and Pfreundschuh, Michael

Published
2018
Full Text
View/download PDF

16. B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Thurner, Lorenz, primary, Fadle, Natalie, additional, Regitz, Evi, additional, Roth, Sophie, additional, Cetin, Onur, additional, Kos, Igor Age, additional, Hess, Simon Mauro, additional, Bein, Julia, additional, Bohle, Rainer Maria, additional, Vornanen, Martine, additional, Sundström, Christer, additional, De Leval, Laurence, additional, Tiacci, Enrico, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Poeschel, Viola, additional, Held, Gerhard, additional, Schwarz, Eva C., additional, Neumann, Frank, additional, Preuss, Klaus-Dieter, additional, Hoth, Markus, additional, Küppers, Ralf, additional, Lehman, Karola, additional, Hansmann, Martin-Leo, additional, Becker, Sören L., additional, Bewarder, Moritz, additional, and Hartmann, Sylvia, additional

Published
2023
Full Text
View/download PDF

17. B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus -Dieter, Hoth, Markus, Kueppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Soeren L., Bewarder, Moritz, Hartmann, Sylvia, Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus -Dieter, Hoth, Markus, Kueppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Soeren L., Bewarder, Moritz, and Hartmann, Sylvia

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD+ lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC and its superantigen MID/hag, associated with extralong CDR3 and HLA-DRB1*04 or HLA-DRB1*07 haplotype. The aim of the present study was to extend the antigen screening to further bacteria and viruses. The fragment antibody-binding (Fab) regions of seven new and 15 previously reported cases were analyzed. The reactivity of non-Moraxella spp.-reactive Fab regions against lysates of Rothia mucilaginosa was observed in 5/22 (22.7%) cases. Galactofuranosyl transferase (Gltf) and 2,3-butanediol dehydrogenase (Bdh) of R. mucilaginosa were identified by comparative silver-and immuno-staining in two-dimensional gels, with subsequent mass spectrometry and validation by western blots and enzyme-linked immunosorbent assay. Both R. mucilaginosa Gltf and Bdh induced BCR pathway activation and proliferation in vitro. Apoptosis was induced by recombinant Gltf/ETA'-immunotoxin conjugates in DEV cells expressing recombinant R. mucilaginosa-reactive BCR. Reactivity against M. catarrhalis RpoC was confirmed in 3/7 newly expressed BCR (total 10/22 reactive to Moraxella spp.), resulting in 15/22 (68.2%) cases with BCR reactivity against defined bacterial antigens. These findings strengthen the hypothesis of bacterial trigger contributing to subsets of NLPHL.

Published
2023
Full Text
View/download PDF

18. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP

Author

Bewarder, Moritz, primary, Kaddu-Mulindwa, Dominic, additional, Kos, Igor Age, additional, Lesan, Vadim, additional, Held, Gerhard, additional, Poeschel, Viola, additional, Thurner, Lorenz, additional, Bittenbring, Joerg Thomas, additional, Schmitz, Norbert, additional, Truemper, Lorenz, additional, Pfreundschuh, Michael, additional, Christofyllakis, Konstantinos, additional, Loeffler, Markus, additional, Altmann, Bettina, additional, and Ziepert, Marita, additional

Published
2023
Full Text
View/download PDF

19. First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

Author

Braulke, Friederike, primary, Zettl, Florian, additional, Ziepert, Marita, additional, Viardot, Andreas, additional, Kahl, Christoph, additional, Prange-Krex, Gabriele, additional, Korfel, Agnieszka, additional, Dreyling, Martin, additional, Bott, Alexander, additional, Wedding, Ulrich, additional, Reichert, Dietmar, additional, de Wit, Maike, additional, Hartmann, Frank, additional, Poeschel, Viola, additional, Schmitz, Norbert, additional, Witzens-Harig, Mathias, additional, Klapper, Wolfram, additional, Rosenwald, Andreas, additional, Wulf, Gerald, additional, Altmann, Bettina, additional, and Trümper, Lorenz, additional

Published
2022
Full Text
View/download PDF

21. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma - a LYSA and GLA/ DSHNHL analysis

Author

Thieblemont, Catherine, primary, Altmann, Bettina, additional, Frontzek, Fabian, additional, Renaud, Loïc, additional, Chartier, Loic, additional, Ketterer, Nicolas, additional, Recher, Christian, additional, Poeschel, Viola, additional, Fitoussi, Olivier, additional, Held, Gerhard, additional, Casasnovas, René-Olivier, additional, Haioun, Corinne, additional, Morschhauser, Franck, additional, Glass, Bertram, additional, Mounier, Nicolas, additional, Tilly, Hervé, additional, Rosenwald, Andreas, additional, Ott, German, additional, Lenz, Georg, additional, Molina, Thierry, additional, Ziepert, Marita, additional, and Schmitz, Norbert, additional

Published
2022
Full Text
View/download PDF

23. Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Houot, Roch, Poeschel, Viola, Altmann, Bettina, Angel, Stephanie, Thurner, Lorenz, Illmer, Thomas, André, Marc, Dreyling, Martin, Maisonneuve, Hervé, Tilly, Hervé, Mayer, Stephanie, Casasnovas, Olivier, Le Gouill, Steven, Offner, Fritz, Cartron, Guillaume, Kerkhoff, Andrea, Weber, Thomas, Hoffmann, Joerg, Ziepert, Marita, Klapper, Wolfram, Itti, Emmanuel, Hellwig, Dirk, Natchkebia, Giorgi, de Leval, Laurence, Rosenwald, Andreas, Haioun, Corinne, Dercle, Laurent, Gaulard, Philippe, Held, Gerhard, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Houot, Roch, Poeschel, Viola, Altmann, Bettina, Angel, Stephanie, Thurner, Lorenz, Illmer, Thomas, André, Marc, Dreyling, Martin, Maisonneuve, Hervé, Tilly, Hervé, Mayer, Stephanie, Casasnovas, Olivier, Le Gouill, Steven, Offner, Fritz, Cartron, Guillaume, Kerkhoff, Andrea, Weber, Thomas, Hoffmann, Joerg, Ziepert, Marita, Klapper, Wolfram, Itti, Emmanuel, Hellwig, Dirk, Natchkebia, Giorgi, de Leval, Laurence, Rosenwald, Andreas, Haioun, Corinne, Dercle, Laurent, Gaulard, Philippe, and Held, Gerhard

Abstract

Supplemental Digital Content is available in the text.

Published
2022

24. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Author

Pfreundschuh, Michael, Kuhnt, Evelyn, Trümper, Lorenz, Österborg, Anders, Trneny, Marek, Shepherd, Lois, Gill, Devinder S, Walewski, Jan, Pettengell, Ruth, Jaeger, Ulrich, Zinzani, Pier-Luigi, Shpilberg, Ofer, Kvaloy, Stein, de Nully Brown, Peter, Stahel, Rolf, Milpied, Noel, López-Guillermo, Armando, Poeschel, Viola, Grass, Sandra, Loeffler, Markus, and Murawski, Niels

Published
2011
Full Text
View/download PDF

25. Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Author

Houot, Roch, primary, Poeschel, Viola, additional, Altmann, Bettina, additional, Angel, Stephanie, additional, Thurner, Lorenz, additional, Illmer, Thomas, additional, Andre, Marc, additional, Dreyling, Martin, additional, Maisonneuve, Hervé, additional, Tilly, Hervé, additional, Mayer, Stephanie, additional, Casasnovas, Olivier, additional, Le Gouill, Steven, additional, Offner, Fritz, additional, Cartron, Guillaume, additional, Kerkhoff, Andrea, additional, Weber, Thomas, additional, Hoffmann, Joerg, additional, Ziepert, Marita, additional, Klapper, Wolfram, additional, Itti, Emmanuel, additional, Hellwig, Dirk, additional, Natchkebia, Giorgi, additional, de Leval, Laurence, additional, Rosenwald, Andreas, additional, Haioun, Corinne, additional, Dercle, Laurent, additional, Gaulard, Philippe, additional, and Held, Gerhard, additional

Published
2022
Full Text
View/download PDF

26. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial

Author

Kaddu-Mulindwa, Dominic, primary, Lesan, Vadim, additional, Berdel, Christian, additional, Stilgenbauer, Stephan, additional, Bewarder, Moritz, additional, Thurner, Lorenz, additional, Witzens-Harig, Mathias, additional, Viardot, Andreas, additional, Soekler, Martin, additional, Keller, Ulrich, additional, Truemper, Lorenz, additional, Christofyllakis, Konstantinos, additional, Fleser, Octavian, additional, Bittenbring, Joerg Thomas, additional, Poeschel, Viola, additional, Held, Gerhard, additional, and Jagoda, Philippe, additional

Published
2021
Full Text
View/download PDF

27. Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas

Author

Hartmann, Sylvia, primary, Scharf, Sonja, additional, Steiner, Yvonne, additional, Loth, Andreas G., additional, Donnadieu, Emmanuel, additional, Flinner, Nadine, additional, Poeschel, Viola, additional, Angel, Stephanie, additional, Bewarder, Moritz, additional, Bein, Julia, additional, Brunnberg, Uta, additional, Bozzato, Alessandro, additional, Schick, Bernhard, additional, Stilgenbauer, Stephan, additional, Bohle, Rainer M., additional, Thurner, Lorenz, additional, and Hansmann, Martin-Leo, additional

Published
2021
Full Text
View/download PDF

28. A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Author

Ziepert, Marita, Altmann, Bettina, Poeschel, Viola, Cristinelli, Caterina, Chartier, Loïc, Ketterer, Nicolas, Recher, Christian, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Mounier, Nicolas, Tilly, Hervé, Morschhauser, Franck, Rosenwald, Andreas, Ott, German, Molina, Thierry Jo, Lenz, Georg, Thieblemont, Catherine, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

29. Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Author

Frontzek, Fabian, Renaud, Loïc, Duehrsen, Ulrich, Poeschel, Viola, Bernard, Sophie, Chartier, Loïc, Ketterer, Nicolas, Recher, Christian, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Rene-Olivier, Haioun, Corinne, Mounier, Nicolas, Tilly, Hervé, Morschhauser, Franck, Le Gouill, Steven, Karsten, Imke E., Duns, Gerben, Steidl, Christian, Scott, David W., Klapper, Wolfram, Rosenwald, Andreas, Ott, German, Molina, Thierry Jo, Lenz, Georg, Ziepert, Marita, Altmann, Bettina, Thieblemont, Catherine, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

30. A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Author

Christofyllakis, Konstantinos, Poeschel, Viola, Altmann, Bettina, Maurer, Stephanie, Lesan, Vadim, Bittenbring, Jörg, Age Kos, Igor, Kaddu-Mulindwa, Dominic, Abdi, Zanir, Fleser, Octavian, Altmeyer, Sarah, Neuendorff, Nina Rosa, Nickelsen, Maike, Held, Gerhard, Dreyling, Martin, Zettl, Florian, Buske, Christian, Lenz, Georg, Glass, Bertram, Chapuy, Bjoern, Schmitz, Norbert, Vassilakopoulos, Theodoros, Ott, German, Siebert, Reiner, Viardot, Andreas, Scherer, Florian, Schmitz, Roland, Rosenwald, Andreas, Hellwig, Dirk, Loeffler, Markus, Stilgenbauer, Stephan, Thurner, Lorenz, Bewarder, Moritz, and Ziepert, Marita

Published
2023
Full Text
View/download PDF

31. R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Author

Held, Gerhard, Altmann, Bettina, Kerkhoff, Andrea, Gastinne, Thomas, Weber, Thomas, Casasnovas, Rene-Olivier, Tilly, Hervé, Da Silva, Maria Gomes, Hoffmann, Jörg, Tonino, Sanne, Vigouroux, Stéphane, Dreyling, Martin, Safar, Violaine, Andre, Marc, Mayer, Stephanie, Morschhauser, Franck, Feugier, Pierre, Scholz, Christian W., Dabrowska-Iwanicka, Anna, Gaulard, Philippe, Molina, Thierry Jo, Rosenwald, Andreas, Greil, Richard, Jaeger, Ulrich, Avigdor, Abraham, Thurner, Lorenz, Maurer, Stephanie, Löffler, Markus, Ziepert, Marita, Haioun, Corinne, Poeschel, Viola, and Houot, Roch

Published
2023
Full Text
View/download PDF

32. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Author

Pfreundschuh, Michael, Schubert, Joerg, Ziepert, Marita, Schmits, Rudolf, Mohren, Martin, Lengfelder, Eva, Reiser, Marcel, Nickenig, Christina, Clemens, Michael, Peter, Norma, Bokemeyer, Carsten, Eimermacher, Hartmut, Ho, Anthony, Hoffmann, Martin, Mertelsmann, Roland, Trümper, Lorenz, Balleisen, Leopold, Liersch, Ruediger, Metzner, Bernd, Hartmann, Frank, Glass, Bertram, Poeschel, Viola, Schmitz, Norbert, Ruebe, Christian, Feller, Alfred C, and Loeffler, Markus

Published
2008
Full Text
View/download PDF

33. CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.

Author

Thieblemont, Catherine, primary, Altmann, Bettina, additional, Casasnovas, Olivier, additional, Frontzek, Fabian, additional, Morschhauser, Franck, additional, Oberic, Lucie, additional, Poeschel, Viola, additional, Fitoussi, Olivier, additional, Renaud, Loïc, additional, Lenz, Georg, additional, Mounier, Nicolas, additional, Rosenwald, Andreas, additional, Ott, German, additional, Molina, Thierry, additional, Parrens, Marie, additional, Chartier, Loic, additional, Ziepert, Marita, additional, Tilly, Herve, additional, and Schmitz, Norbert, additional

Published
2021
Full Text
View/download PDF

34. Relapsed / Refractory International Prognostic Index (R/R-IPI):An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma

Author

Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., de Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, Salles, Gilles, Shi, Qian, El-Galaly, Tarec C., Habermann, Thomas M., Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., de Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, Salles, Gilles, Shi, Qian, El-Galaly, Tarec C., and Habermann, Thomas M.

Abstract

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.

Published
2021

35. Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

Author

Maurer, Matthew J., primary, Jakobsen, Lasse H., additional, Mwangi, Raphael, additional, Schmitz, Norbert, additional, Farooq, Umar, additional, Flowers, Cristopher R., additional, Nully Brown, Peter, additional, Thompson, Carrie A., additional, Frederiksen, Henrik, additional, Cunningham, David, additional, Jørgensen, Judit, additional, Poeschel, Viola, additional, Nowakowski, Grzegorz, additional, Seymour, John F., additional, Merli, Francesco, additional, Haioun, Corinne, additional, Ghesquieres, Hervé, additional, Ziepert, Marita, additional, Tilly, Hervé, additional, Salles, Gilles, additional, Shi, Qian, additional, El‐Galaly, Tarec C., additional, and Habermann, Thomas M., additional

Published
2021
Full Text
View/download PDF

36. A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Author

Schmitz, Norbert, primary, Truemper, Lorenz H, additional, Bouabdallah, Krimo, additional, Ziepert, Marita, additional, Leclerc, Mathieu, additional, Cartron, Guillaume, additional, Jaccard, Arnaud, additional, Reimer, Peter, additional, Wagner-Drouet, Eva Maria, additional, Wilhelm, Martin, additional, Sanhes, Laurence, additional, Lamy, Thierry, additional, de Leval, Laurence, additional, Rosenwald, Andreas, additional, Roussel, Murielle, additional, Kroschinsky, Frank P, additional, Lindemann, Walter Walter, additional, Dreger, Peter, additional, Viardot, Andreas, additional, Milpied, Noel J, additional, Gisselbrecht, Christian, additional, Wulf, Gerald G, additional, Gyan, Emmanuel, additional, Gaulard, Philippe, additional, Bay, Jacques-Olivier, additional, Glass, Bertram, additional, Poeschel, Viola, additional, Damaj, Gandhi, additional, Sibon, David, additional, Delmer, Alain Jacques, additional, Bilger, Karin, additional, Banos, Anne, additional, Haenel, Mathias, additional, Dreyling, Martin, additional, Metzner, Bernd, additional, Keller, Ulrich, additional, Braulke, Friederike, additional, Friedrichs, Birte, additional, Nickelsen, Maike, additional, Altmann, Bettina, additional, and Tournilhac, Olivier, additional

Published
2020
Full Text
View/download PDF

37. Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Author

Jabs, Jonas Matthias, primary, Poeschel, Viola, additional, Sökler, Martin, additional, Habersang, Kerstin, additional, Mahlberg, Rolf, additional, Keller, Ulrich, additional, Hoeffkes, Heinz-Gert, additional, Rank, Andreas, additional, Viardot, Andreas, additional, Neubauer, Andreas, additional, Ziepert, Marita, additional, Altmann, Bettina, additional, Stilgenbauer, Stephan, additional, Pfreundschuh, Michael, additional, Held, Gerhard, additional, and Bittenbring, Joerg Thomas, additional

Published
2020
Full Text
View/download PDF

38. Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Author

Thurner, Lorenz, primary, Poeschel, Viola, additional, Altmann, Bettina, additional, Tilly, Herve, additional, Andre, Marc, additional, Maerevoet, Marie, additional, Weber, Thomas, additional, Hoffmann, Joerg, additional, Dreyling, Martin, additional, Maisonneuve, Herve, additional, Kerkhoff, Andrea, additional, Le Gouill, Steven, additional, Stilgenbauer, Stephan, additional, Ziepert, Marita, additional, Houot, Roch, additional, Haioun, Corinne, additional, and Held, Gerhard, additional

Published
2020
Full Text
View/download PDF

39. Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Author

Houot, Roch, primary, Poeschel, Viola, additional, Altmann, Bettina, additional, Illmer, Thomas, additional, André, Marc, additional, Dreyling, Martin, additional, Maisonneuve, Herve, additional, Tilly, Herve, additional, Mayer, Stephanie, additional, Casasnovas, Rene-Olivier, additional, Le Gouill, Steven, additional, Offner, Fritz C., additional, Cartron, Guillaume, additional, Kerkhoff, Andrea, additional, Weber, Thomas, additional, Hoffmann, Joerg, additional, Ziepert, Marita, additional, Klapper, Wolfram, additional, Itti, Emmanuel, additional, Hellwig, Dirk, additional, De Leval, Laurence, additional, Rosenwald, Andreas, additional, Haioun, Corinne, additional, Dercle, Laurent, additional, Gaulard, Philippe, additional, and Held, Gerhard, additional

Published
2020
Full Text
View/download PDF

41. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.

Author

Kaddu-Mulindwa, Dominic, Lesan, Vadim, Berdel, Christian, Stilgenbauer, Stephan, Bewarder, Moritz, Thurner, Lorenz, Witzens-Harig, Mathias, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Truemper, Lorenz, Christofyllakis, Konstantinos, Fleser, Octavian, Bittenbring, Joerg Thomas, Poeschel, Viola, Held, Gerhard, and Jagoda, Philippe

Subjects
BONE density, ANTINEOPLASTIC combined chemotherapy protocols, DIFFUSE large B-cell lymphomas
Abstract

Patients with diffuse large B-cell lymphoma (DLBCL) treated with the R-CHOP regime receive a high cumulative dose of prednisone. We used computer tomography-ascertained Hounsfield units (HU) as a surrogate parameter for bone mineral density (BMD) in three different locations of the L3 vertebral body at baseline and post-treatment. HU were measured in 50 patients with DLBCL of the previously published FLYER-trial which compared four cycles of R-CHOP + 2 × rituximab infusion to six cycles of R-CHOP in young, favorable DLBCL patients. In total, median loss was 26.8 HU in all patients over time. The median HU loss was significantly lower in the four cycles arm (21.3 HU vs. 41.3 HU, p = 0.023). In conclusion, young patients with DLBCL receiving R-CHOP have significant HU/BMD loss under treatment with R-CHOP. Patients receiving four cycles of R-CHOP had less HU/BMD loss than patients receiving six cycles. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).

Author

Held, Gerhard, Thurner, Lorenz, Poeschel, Viola, Berdel, Christian, Ott, German, Schmidt, Christian, Viardot, Andreas, Borchmann, Peter, Shpilberg, Ofer, Nickelsen, Maike, Federico, Massimo, Brown, Peter de Nully, Murawski, Niels, Trumper, Lorenz H., Schmidberger, Heinz, Ruebe, Christian, Fleckenstein, Jochen, Schmitz, Norbert, Loeffler, Markus, Ziepert, Marita, Alliance, German Lymphoma, Held, Gerhard, Thurner, Lorenz, Poeschel, Viola, Berdel, Christian, Ott, German, Schmidt, Christian, Viardot, Andreas, Borchmann, Peter, Shpilberg, Ofer, Nickelsen, Maike, Federico, Massimo, Brown, Peter de Nully, Murawski, Niels, Trumper, Lorenz H., Schmidberger, Heinz, Ruebe, Christian, Fleckenstein, Jochen, Schmitz, Norbert, Loeffler, Markus, Ziepert, Marita, and Alliance, German Lymphoma

Published
2020

43. Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Author

Zettl, Florian, primary, Braulke, Friederike, additional, Ziepert, Marita, additional, Viardot, Andreas, additional, Kahl, Christoph, additional, Prange-Krex, Gabriele, additional, Korfel, Agnieszka, additional, Dreyling, Martin H., additional, Illmer, Thomas, additional, Birkmann, Josef, additional, Wedding, Ulrich, additional, Reichert, Dietmar, additional, Wit, Maike de, additional, Hartmann, Frank, additional, Hurtz, Hans-Juergen, additional, Schmitz, Norbert, additional, Witzens-Harig, Mathias, additional, Klapper, Wolfram, additional, Rosenwald, Andreas, additional, Poeschel, Viola, additional, Loeffler, Markus, additional, Wulf, Gerald, additional, Altmann, Bettina, additional, and Truemper, Lorenz, additional

Published
2019
Full Text
View/download PDF

44. Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Author

Held, Gerhard, primary, Haioun, Corinne, additional, Houot, Roch, additional, Gaulard, Philippe, additional, Molina, Thierry, additional, Rosenwald, Andreas, additional, André, Marc, additional, Hoffmann, Joerg, additional, Dreyling, Martin, additional, Casasnovas, Olivier, additional, Maisonneuve, Herve, additional, Tilly, Herve, additional, Illmer, Thomas, additional, Mayer, Stephanie, additional, Kirchen, Heinz, additional, La Rosée, Paul, additional, Loeffler, Markus, additional, Ziepert, Marita, additional, Altmann, Bettina, additional, and Poeschel, Viola, additional

Published
2019
Full Text
View/download PDF

45. Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx), Plus Rituximab (R) in Case of B-Cell Lymphoma

Author

Held, Gerhard, primary, Houot, Roch, additional, Avigdor, Abraham, additional, André, Marc, additional, Dabrowska-Iwanicka, Anna, additional, Jaeger, Ulrich, additional, Tonino, Sanne, additional, Trneny, Marek, additional, Maria, Gomes da Silva, additional, Gaulard, Philippe, additional, Molina, Thierry Jo, additional, Rosenwald, Andreas, additional, Rymkiewicz, Grzegorz, additional, Fest, Thierry, additional, Tarte, Karin, additional, Loeffler, Markus, additional, Ziepert, Marita, additional, Altmann, Bettina, additional, Poeschel, Viola, additional, and Haioun, Corinne, additional

Published
2019
Full Text
View/download PDF

46. Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Author

Maurer, Matthew J., primary, Jakobsen, Lasse H., primary, Schmitz, Norbert, primary, Farooq, Umar, primary, Flowers, Christopher R., primary, Brown, Peter de Nully, primary, Thompson, Carrie A., primary, Frederiksen, Henrik, primary, Cunningham, David, primary, Jørgensen, Judit, primary, Poeschel, Viola, primary, Nowakowski, Grzegorz, primary, Seymour, John F., primary, Merli, Francesco, primary, Haioun, Corinne, primary, Ghesquieres, Herve, primary, Ziepert, Marita, primary, Tilly, Herve, primary, Salles, Gilles, primary, Shi, Qian, primary, El-Galaly, Tarec Christoffer C., primary, and Habermann, Thomas M., primary

Published
2019
Full Text
View/download PDF

47. Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma

Author

Kaddu-Mulindwa, Dominic, primary, Altmann, Bettina, additional, Held, Gerhard, additional, Ziepert, Marita, additional, Menhart, Karin, additional, Grosse, Jirka, additional, Angel, Stephanie, additional, Stilgenbauer, Stephan, additional, Pfreundschuh, Michael, additional, Herrmann, Ken, additional, Duehrsen, Ulrich, additional, Hüttmann, Andreas, additional, Barbato, Francesco, additional, Hellwig, Dirk, additional, and Poeschel, Viola, additional

Published
2019
Full Text
View/download PDF

48. Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).

Author

Ruppert, Amy S., primary, Dixon, Jesse G., additional, Salles, Gilles A., additional, Wall, Anna K. M., additional, Cunningham, David, additional, Poeschel, Viola, additional, Haioun, Corinne, additional, Tilly, Herve, additional, Ghesquieres, Herve, additional, Ziepert, Marita, additional, Flament, Jocelyne, additional, Flowers, Christopher, additional, Shi, Qian, additional, and Shmitz, Norbert, additional

Published
2019
Full Text
View/download PDF

49. Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma.

Author

Maurer, Matthew J., Jakobsen, Lasse H., Mwangi, Raphael, Schmitz, Norbert, Farooq, Umar, Flowers, Cristopher R., Nully Brown, Peter, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Hervé, Ziepert, Marita, Tilly, Hervé, and Salles, Gilles

Published
2021
Full Text
View/download PDF

50. Reduction of Chemotherapy in Aggressive Non-Hodgkin's Lymphoma with Favorable Prognosis

Author

Poeschel, Viola, primary, Held, Gerhard, additional, Ziepert, Marita, additional, Witzens-Harig, Mathias, additional, Holte, Harald, additional, Thurner, Lorenz, additional, Borchmann, Peter, additional, Viardot, Andreas, additional, Soekler, Martin, additional, Keller, Ulrich, additional, Schmidt, Christian, additional, Trümper, Lorenz, additional, Mahlberg, Rolf, additional, Marks, Reinhard, additional, Hoeffkes, Heinz-Gert, additional, Metzner, Bernd, additional, Dierlamm, Judith, additional, Frickhofen, Norbert, additional, Hänel, Mathias, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Merli, Francesco, additional, Tucci, Alessandra, additional, Brown, Peter de Nully, additional, Federico, Massimo, additional, Lengfelder, Eva, additional, Rocco, Alice di, additional, Trappe, Ralf, additional, Rosenwald, Andreas, additional, Berdel, Christian, additional, Maisenhölder, Martin, additional, Shpilberg, Ofer, additional, Amam, Josif, additional, Christofyllakis, Konstantinos, additional, Hartmann, Frank, additional, Murawski, Niels, additional, Stilgenbauer, Stephan, additional, Schmitz, Norbert, additional, Altmann, Bettina, additional, Loeffler, Markus, additional, Pfreundschuh, Michael, additional, and Investigators, FLYER Trial, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results